SynthesisPloS one2022
Global epidemiology of occult hepatitis B virus infections in blood donors, a systematic review and meta-analysis.
Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Occult HBV among anti-HBc-reactive blood donors in Colombia: low HBsAg prevalence, genotype F3, and small-S variation relevant to HBsAg detectability.Scientific reports · 2026Article
- Characteristics of occult hepatitis B infection among pregnant women in the Center Region of Cameroon: rationale for universal administration of hepatitis B birth dose vaccine.BMC pregnancy and childbirth · 2026Article
- Implications of occult hepatitis B infection for blood donor management: a five-year evaluation from Western Saudi Arabia.BMC infectious diseases · 2026Article
- Hepatitis B immune escape and drug resistance mutations among blood donors in Gabon during the year 2022.Scientific reports · 2026Article
- Occult hepatitis B infection.Hepatology forum · 2026Review
- Article
- Reentry of voluntary blood donors in Chongqing, China (2022-2024): a retrospective single-center analysis.Frontiers in medicine · 2026Article
- Residual transfusion risk of occult hepatitis B transmission associated to genotypes A and E among blood donors in Yaoundé, Cameroon.BMC infectious diseases · 2025Article
- Prevalence and Implications of Occult Hepatitis B Virus Infection Among Blood Donors in Saudi Arabia: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- Transfusion-transmitted occult hepatitis B virus infection: current understanding, challenges, and its implication in blood safety.Frontiers in immunology · 2025Review
- Occult HBV Infection in Patients Infected by HIV or HCV: Comparison between HBV-DNA and Two Assays for HBsAg.Viruses · 2024Article
- Article
- The burden of liver cancer in Mongolia from 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Frontiers in oncology · 2024Article
- Prevalence of antibody to hepatitis B surface antigen among qualified blood donors in Nanjing, China.Human vaccines & immunotherapeutics · 2023Article
- Prevalence of occult hepatitis B virus infection in Egypt: a systematic review with meta-analysis.The Journal of the Egyptian Public Health Association · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 6 institutions in 1 country.
Funding
Abstract
This study aimed to assess the global prevalence of occult hepatitis B in blood donors. We searched PubMed, Web of Science, Global Index Medicus, and Excerpta Medica Database. Study selection and data extraction were performed by at least two independent investigators. Heterogeneity (I2) was assessed using the χ2 test on the Cochran Q statistic and H parameters. Sources of heterogeneity were explored by subgroup analyses. This study is registered with PROSPERO, number CRD42021252787. We included 82 studies in this meta-analysis. The overall prevalence of OBI was 6.2% (95% CI: 5.4-7.1) in HBsAg negative and anti-HBc positive blood donors. Only sporadic cases of OBI were reported in HBsAg negative and anti-HBc negative blood donors. The overall prevalence of OBI was 0.2% (95% CI: 0.1-0.4) in HBsAg negative blood donors. The prevalence of OBI was generally higher in countries with low-income economic status. The results of this study show that despite routine screening of blood donors for hepatitis B, the transmission of HBV by blood remains possible via OBI and/or a seronegative window period; hence there is a need for active surveillance and foremost easier access to molecular tests for the screening of blood donors before transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.